188 related articles for article (PubMed ID: 34855561)
1. Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
Kim H; Kim H; Kim R; Jo H; Kim HR; Hong J; Park JO; Park YS; Kim ST
Technol Cancer Res Treat; 2021; 20():15330338211062324. PubMed ID: 34855561
[No Abstract] [Full Text] [Related]
2. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
5. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
9. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.
Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
Ther Adv Med Oncol; 2021; 13():1758835921992992. PubMed ID: 33717226
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
11. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
13. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
14. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
15. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
16. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
Sun LY; Cen WJ; Tang WT; Long YK; Yang XH; Ji XM; Yang JJ; Zhang RJ; Wang F; Shao JY; Du ZM
Cancer Med; 2021 Oct; 10(19):6610-6617. PubMed ID: 34469045
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
20. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.
Liddell SS; Chakrabarti S; Wintheiser GA; Zemla TJ; Shi Q; Tella SH; Jin Z; Wookey VB; Hassan H; Tran NH; Borad MJ; Mahipal A
JCO Precis Oncol; 2022 Jun; 6():e2200003. PubMed ID: 35772047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
